Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data

Quartuccio, Luca; Zabotti, Alen; Zotto, Stefania Del; Zanier, Loris; Vita, Salvatore De; Valent, Francesca

doi:10.1016/j.jare.2018.09.003

Cited by 51 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding safety issues, there are several side effects of TNF-α inhibitors. General side effects of all TNF-α inhibitors involve headaches, rashes, anemia, transaminitis, infectious, and, most commonly, an injection site reaction through a subcutaneous route [ 90 , 91 ]. The worsening of heart failure and increased risk of developing tuberculosis as well as lymphoma are significantly observed in patients who have autoimmune diseases compared to healthy people [ 92 , 93 , 94 ].…”

Section: Conclusion and Discussionmentioning

confidence: 99%

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics

Jang

Lee

Shin

et al. 2021

IJMS

848

377

View full text Add to dashboard Cite

Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases. TNF-α binds to two different receptors, which initiate signal transduction pathways. These pathways lead to various cellular responses, including cell survival, differentiation, and proliferation. However, the inappropriate or excessive activation of TNF-α signaling is associated with chronic inflammation and can eventually lead to the development of pathological complications such as autoimmune diseases. Understanding of the TNF-α signaling mechanism has been expanded and applied for the treatment of immune diseases, which has resulted in the development of effective therapeutic tools, including TNF-α inhibitors. Currently, clinically approved TNF-α inhibitors have shown noticeable potency in a variety of autoimmune diseases, and novel TNF-α signaling inhibitors are being clinically evaluated. In this review, we briefly introduce the impact of TNF-α signaling on autoimmune diseases and its inhibitors, which are used as therapeutic agents against autoimmune diseases.

show abstract

Section: Conclusion and Discussionmentioning

confidence: 99%

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics

Jang

Lee

Shin

et al. 2021

IJMS

848

377

View full text Add to dashboard Cite

show abstract

“…Early in the pandemic, there was lack of evidence whether immunosuppressive drugs could be continued safely although NICE guidelines advised continuing patients on their biologic therapy. The risk of infections was thought to be slightly raised when patients with chronic inflammatory arthritis are treated with biologic anti-rheumatic drugs, particularly in elderly patients with co-morbidities [ 17 ]. The rationale to continue biologic drugs is mainly based on expert opinion and their clinical experience with the notion that the continuation of immunosuppressive drugs would minimise the disease flares and subsequent hospital admissions during the pandemic [ 5 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 on rheumatology practice in the UK—a pan-regional rheumatology survey

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has disrupted healthcare services and rheumatology staff were redeployed to the frontline. The purpose of this survey was to evaluate the impact of the COVID-19 pandemic on the provision of rheumatology services as viewed by rheumatologists in the UK. Survey monkey questionnaire weblink was sent to 804 clinicians including consultant rheumatologists, speciality trainees, nurse specialists, and allied health professionals in 4 regions of the UK to evaluate personal effects of COVID-19 and redeployment, impact on current out-patient clinic activity, immunosuppressive drug use, and future rheumatology care. Response rate was 21%. One-fifth of the responders reported that their rheumatology departments were functioning less than 50% capacity during the pandemic. Two-third of responders felt anxious about the ill-effects of COVID-19 on their health and well-being, and one-third of them were redeployed. During the peak of the pandemic, 75% of clinicians stopped intravenous biologics. Although access to video consultation was available for up to three-fourths of the clinicians, the majority (90%) used this modality in less than 1 in 4 consultations. This survey highlights rheumatologists' perception in the delivery of future care and anxiety they faced. As demonstrated by this survey, the National Institute for Health and Care Excellence (NICE) guidance did not influence clinician decision making in some aspects of patient care. Underutilization of tele-rheumatology in this survey should be considered whilst planning the restoration of rheumatology services in the post-COVID era.

show abstract

“…First, chronic patients may be more often symptomatic or have increased disease severity. Then, patients with chronic conditions may have an overall risk of SARS-CoV-2 infection (of any severity) different from the general population, either because some chronic conditions might themselves increase the risk of being infected after a contact with a COVID-19 case, or because of the medications used to treat the disease [ 20 , 21 ]. Then, patients with a chronic condition may be exposed to sources of infection differently from the general population: they may be less exposed if they are more prone to remain at home or more exposed if they need to attend hospitals where the virus may spread easily.…”

Section: Discussionmentioning

confidence: 99%

Frequency of nasopharyngeal swab collection and positivity for SARS-CoV-2 infection in the population of the Italian province of Udine with and without chronic conditions

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data

Abstract: Graphical abstract

Cited by 51 publications

References 27 publications

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics

Impact of COVID-19 on rheumatology practice in the UK—a pan-regional rheumatology survey

Frequency of nasopharyngeal swab collection and positivity for SARS-CoV-2 infection in the population of the Italian province of Udine with and without chronic conditions

Contact Info

Product

Resources

About